| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rad51 Recombinase | 13 | 2021 | 80 | 4.140 |
Why?
|
| Homologous Recombination | 9 | 2022 | 51 | 2.560 |
Why?
|
| Radiation Injuries | 3 | 2019 | 156 | 1.410 |
Why?
|
| DNA Repair | 12 | 2021 | 356 | 1.270 |
Why?
|
| Radiotherapy | 5 | 2019 | 328 | 1.190 |
Why?
|
| Endometrial Neoplasms | 11 | 2001 | 193 | 1.120 |
Why?
|
| Small Molecule Libraries | 3 | 2016 | 61 | 1.010 |
Why?
|
| Neoplasms | 7 | 2016 | 2898 | 0.920 |
Why?
|
| Enzyme Inhibitors | 2 | 2019 | 639 | 0.880 |
Why?
|
| Morpholines | 3 | 2015 | 65 | 0.880 |
Why?
|
| Transcription Factor RelB | 1 | 2022 | 7 | 0.870 |
Why?
|
| Benzamides | 3 | 2015 | 229 | 0.790 |
Why?
|
| Sulfonamides | 3 | 2015 | 300 | 0.720 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2019 | 109 | 0.690 |
Why?
|
| Quinoxalines | 1 | 2019 | 50 | 0.680 |
Why?
|
| Pyrroles | 4 | 2019 | 184 | 0.670 |
Why?
|
| NF-kappa B | 1 | 2022 | 447 | 0.670 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 128 | 0.650 |
Why?
|
| Antineoplastic Agents | 5 | 2016 | 2360 | 0.640 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 1075 | 0.610 |
Why?
|
| Anthracyclines | 1 | 2017 | 37 | 0.590 |
Why?
|
| DNA Helicases | 2 | 2015 | 82 | 0.590 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 330 | 0.570 |
Why?
|
| Sarcoma | 3 | 2019 | 215 | 0.550 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 162 | 0.550 |
Why?
|
| DNA Replication | 4 | 2019 | 164 | 0.530 |
Why?
|
| Lung Neoplasms | 8 | 2023 | 2262 | 0.530 |
Why?
|
| Enzyme Activation | 2 | 2013 | 692 | 0.510 |
Why?
|
| Head and Neck Neoplasms | 2 | 2016 | 1052 | 0.490 |
Why?
|
| Radiotherapy, Conformal | 2 | 2007 | 83 | 0.490 |
Why?
|
| Humans | 59 | 2023 | 86648 | 0.470 |
Why?
|
| Drug Therapy | 1 | 2014 | 70 | 0.470 |
Why?
|
| Adenocarcinoma | 6 | 2012 | 1169 | 0.470 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2013 | 41 | 0.460 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2013 | 52 | 0.460 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 1197 | 0.460 |
Why?
|
| Rec A Recombinases | 1 | 2013 | 14 | 0.460 |
Why?
|
| Maleimides | 1 | 2012 | 29 | 0.450 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 705 | 0.440 |
Why?
|
| DNA Damage | 3 | 2017 | 366 | 0.430 |
Why?
|
| Radiotherapy, Adjuvant | 8 | 2009 | 292 | 0.430 |
Why?
|
| Escherichia coli Proteins | 1 | 2013 | 179 | 0.410 |
Why?
|
| Indoles | 1 | 2013 | 318 | 0.410 |
Why?
|
| DNA Breaks, Double-Stranded | 3 | 2022 | 64 | 0.400 |
Why?
|
| Cisplatin | 4 | 2009 | 612 | 0.390 |
Why?
|
| DNA-Binding Proteins | 4 | 2021 | 1214 | 0.390 |
Why?
|
| HEK293 Cells | 4 | 2019 | 617 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 2438 | 0.370 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2023 | 1313 | 0.360 |
Why?
|
| Neoplasm Staging | 15 | 2023 | 1938 | 0.350 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2009 | 468 | 0.350 |
Why?
|
| Protein Binding | 5 | 2019 | 1462 | 0.350 |
Why?
|
| Cell Survival | 4 | 2019 | 971 | 0.340 |
Why?
|
| Breast Neoplasms | 3 | 2021 | 2904 | 0.330 |
Why?
|
| Molecular Structure | 3 | 2019 | 287 | 0.330 |
Why?
|
| Prognosis | 13 | 2021 | 3681 | 0.330 |
Why?
|
| DNA | 6 | 2021 | 1295 | 0.320 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2007 | 49 | 0.310 |
Why?
|
| Female | 35 | 2021 | 44561 | 0.310 |
Why?
|
| Cranial Irradiation | 1 | 2007 | 36 | 0.310 |
Why?
|
| Apoptosis | 3 | 2019 | 1689 | 0.310 |
Why?
|
| Aged | 25 | 2021 | 18406 | 0.310 |
Why?
|
| Follow-Up Studies | 11 | 2021 | 3639 | 0.300 |
Why?
|
| Structure-Activity Relationship | 3 | 2019 | 408 | 0.300 |
Why?
|
| Retrospective Studies | 19 | 2023 | 8475 | 0.290 |
Why?
|
| Nasolacrimal Duct | 1 | 2006 | 2 | 0.280 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 2006 | 3 | 0.280 |
Why?
|
| Genomic Instability | 3 | 2017 | 79 | 0.280 |
Why?
|
| Intubation | 1 | 2006 | 21 | 0.280 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 2427 | 0.280 |
Why?
|
| Middle Aged | 27 | 2021 | 25026 | 0.270 |
Why?
|
| Ovariectomy | 3 | 2001 | 81 | 0.260 |
Why?
|
| Adult | 23 | 2021 | 25647 | 0.250 |
Why?
|
| Hysterectomy | 3 | 2001 | 146 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2021 | 592 | 0.240 |
Why?
|
| Multiprotein Complexes | 2 | 2021 | 95 | 0.230 |
Why?
|
| Genes, p53 | 1 | 2003 | 109 | 0.220 |
Why?
|
| Fractures, Spontaneous | 1 | 2023 | 11 | 0.220 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2004 | 91 | 0.220 |
Why?
|
| Attitude to Health | 1 | 2004 | 220 | 0.220 |
Why?
|
| Combined Modality Therapy | 6 | 2013 | 1686 | 0.220 |
Why?
|
| Treatment Outcome | 13 | 2017 | 7981 | 0.220 |
Why?
|
| Survival Analysis | 9 | 2017 | 1540 | 0.220 |
Why?
|
| HIV-1 | 2 | 2015 | 164 | 0.220 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1464 | 0.210 |
Why?
|
| Adenoviridae | 1 | 2003 | 345 | 0.210 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 763 | 0.210 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 6510 | 0.200 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2003 | 164 | 0.200 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2023 | 98 | 0.200 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 42 | 0.200 |
Why?
|
| Pelvic Neoplasms | 1 | 2001 | 45 | 0.200 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 104 | 0.200 |
Why?
|
| Orthopedic Procedures | 1 | 2023 | 127 | 0.200 |
Why?
|
| Genetic Therapy | 1 | 2003 | 343 | 0.200 |
Why?
|
| Orthopedics | 1 | 2023 | 121 | 0.190 |
Why?
|
| Brachytherapy | 6 | 2001 | 119 | 0.190 |
Why?
|
| Peptides | 1 | 2004 | 639 | 0.190 |
Why?
|
| Extremities | 2 | 2013 | 165 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 5 | 2001 | 552 | 0.180 |
Why?
|
| Ossification, Heterotopic | 1 | 2019 | 33 | 0.180 |
Why?
|
| Adnexa Uteri | 1 | 1999 | 12 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 137 | 0.170 |
Why?
|
| Cycloaddition Reaction | 1 | 2019 | 6 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2003 | 383 | 0.170 |
Why?
|
| Radiotherapy Dosage | 4 | 2009 | 468 | 0.170 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 388 | 0.170 |
Why?
|
| Prostatic Neoplasms | 2 | 2001 | 1721 | 0.170 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 126 | 0.170 |
Why?
|
| Survival Rate | 7 | 2021 | 1864 | 0.170 |
Why?
|
| Naphthyridines | 1 | 2019 | 53 | 0.160 |
Why?
|
| Radiobiology | 1 | 2018 | 13 | 0.160 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 373 | 0.160 |
Why?
|
| Male | 17 | 2021 | 40990 | 0.160 |
Why?
|
| MCF-7 Cells | 2 | 2015 | 106 | 0.150 |
Why?
|
| Lymphatic Metastasis | 4 | 2012 | 486 | 0.150 |
Why?
|
| Prostate-Specific Antigen | 1 | 1999 | 353 | 0.150 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2007 | 188 | 0.150 |
Why?
|
| Pneumonectomy | 2 | 2011 | 196 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2017 | 90 | 0.150 |
Why?
|
| Endosonography | 1 | 2017 | 96 | 0.140 |
Why?
|
| Bronchi | 1 | 2017 | 229 | 0.140 |
Why?
|
| Risk | 3 | 2004 | 674 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2021 | 631 | 0.140 |
Why?
|
| Neuroblastoma | 1 | 2019 | 375 | 0.130 |
Why?
|
| Disease-Free Survival | 6 | 2011 | 1204 | 0.130 |
Why?
|
| Doxorubicin | 2 | 2009 | 295 | 0.130 |
Why?
|
| Neoplasm Metastasis | 3 | 2011 | 1056 | 0.130 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2012 | 56 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2012 | 1077 | 0.120 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 392 | 0.110 |
Why?
|
| Fluorometry | 1 | 2013 | 30 | 0.110 |
Why?
|
| RNA Interference | 1 | 2014 | 370 | 0.110 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2013 | 94 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2000 | 275 | 0.110 |
Why?
|
| Mitomycin | 1 | 2012 | 29 | 0.110 |
Why?
|
| Chicago | 3 | 2001 | 1380 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 318 | 0.110 |
Why?
|
| Stress, Physiological | 1 | 2014 | 227 | 0.110 |
Why?
|
| Mice, Nude | 1 | 2014 | 789 | 0.110 |
Why?
|
| Actuarial Analysis | 3 | 2001 | 66 | 0.110 |
Why?
|
| DNA, Single-Stranded | 2 | 2011 | 92 | 0.100 |
Why?
|
| Cross-Linking Reagents | 1 | 2012 | 86 | 0.100 |
Why?
|
| Protein Subunits | 1 | 2012 | 123 | 0.100 |
Why?
|
| Virus Integration | 1 | 2011 | 16 | 0.100 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 39 | 0.100 |
Why?
|
| Cystadenocarcinoma, Papillary | 2 | 2001 | 9 | 0.100 |
Why?
|
| Life Tables | 2 | 2001 | 48 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 114 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2022 | 3267 | 0.100 |
Why?
|
| Dinoprostone | 1 | 2011 | 69 | 0.100 |
Why?
|
| Cysteine | 1 | 2012 | 135 | 0.100 |
Why?
|
| Esophageal Neoplasms | 2 | 2007 | 322 | 0.100 |
Why?
|
| Mice | 3 | 2019 | 11439 | 0.100 |
Why?
|
| Chromatin | 1 | 2014 | 384 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2011 | 159 | 0.100 |
Why?
|
| Age Factors | 3 | 2007 | 1849 | 0.100 |
Why?
|
| Animals | 4 | 2019 | 26704 | 0.100 |
Why?
|
| Child | 2 | 2016 | 6928 | 0.100 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2001 | 62 | 0.100 |
Why?
|
| Radiation Oncology | 1 | 2013 | 119 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2000 | 999 | 0.100 |
Why?
|
| Binding Sites | 1 | 2012 | 1104 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2011 | 508 | 0.090 |
Why?
|
| Epirubicin | 1 | 2009 | 14 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 269 | 0.090 |
Why?
|
| Ifosfamide | 1 | 2009 | 49 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2204 | 0.090 |
Why?
|
| Amino Acid Sequence | 2 | 2021 | 2065 | 0.080 |
Why?
|
| History, 19th Century | 1 | 2009 | 59 | 0.080 |
Why?
|
| Necrosis | 1 | 2009 | 204 | 0.080 |
Why?
|
| Enzyme Stability | 1 | 2008 | 39 | 0.080 |
Why?
|
| Radiosurgery | 1 | 2011 | 272 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2009 | 290 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2009 | 175 | 0.080 |
Why?
|
| Quality of Life | 1 | 2016 | 1587 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2009 | 312 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 915 | 0.080 |
Why?
|
| Platinum Compounds | 1 | 2007 | 31 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2006 | 286 | 0.080 |
Why?
|
| Ligands | 1 | 2008 | 433 | 0.070 |
Why?
|
| Genes, BRCA2 | 1 | 2008 | 160 | 0.070 |
Why?
|
| Glutamates | 1 | 2007 | 89 | 0.070 |
Why?
|
| Dacryocystorhinostomy | 1 | 2006 | 4 | 0.070 |
Why?
|
| Silicones | 1 | 2006 | 16 | 0.070 |
Why?
|
| Guanine | 1 | 2007 | 208 | 0.070 |
Why?
|
| Carboplatin | 1 | 2007 | 286 | 0.070 |
Why?
|
| Fibroblasts | 1 | 2008 | 731 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2017 | 2763 | 0.060 |
Why?
|
| London | 1 | 2004 | 16 | 0.060 |
Why?
|
| Bacteriophage M13 | 1 | 2004 | 9 | 0.060 |
Why?
|
| Adolescent | 3 | 2007 | 8981 | 0.060 |
Why?
|
| Safe Sex | 1 | 2004 | 23 | 0.060 |
Why?
|
| Pregnancy in Adolescence | 1 | 2004 | 25 | 0.060 |
Why?
|
| Condoms | 1 | 2004 | 36 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2004 | 173 | 0.060 |
Why?
|
| Radiation, Ionizing | 1 | 2004 | 121 | 0.060 |
Why?
|
| Peptide Library | 1 | 2004 | 84 | 0.060 |
Why?
|
| Focus Groups | 1 | 2004 | 155 | 0.060 |
Why?
|
| Awareness | 1 | 2004 | 93 | 0.060 |
Why?
|
| Risk Reduction Behavior | 1 | 2004 | 98 | 0.060 |
Why?
|
| Radiation Tolerance | 1 | 2004 | 168 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2006 | 840 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1759 | 0.060 |
Why?
|
| Stents | 1 | 2006 | 377 | 0.060 |
Why?
|
| HIV Infections | 1 | 2011 | 773 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2008 | 2380 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2003 | 155 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 560 | 0.050 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2001 | 12 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2003 | 440 | 0.050 |
Why?
|
| Platinum | 1 | 2021 | 63 | 0.050 |
Why?
|
| Young Adult | 2 | 2013 | 5976 | 0.050 |
Why?
|
| Vaginal Neoplasms | 1 | 2001 | 83 | 0.050 |
Why?
|
| Infant | 1 | 2007 | 3048 | 0.050 |
Why?
|
| China | 1 | 2021 | 228 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2021 | 416 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1596 | 0.050 |
Why?
|
| Cryoelectron Microscopy | 1 | 2021 | 91 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2007 | 3612 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 1960 | 0.050 |
Why?
|
| Vascular Neoplasms | 1 | 2000 | 19 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2001 | 150 | 0.050 |
Why?
|
| Nucleic Acid Conformation | 1 | 2021 | 332 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 1999 | 567 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2007 | 2261 | 0.050 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2000 | 100 | 0.050 |
Why?
|
| Carcinoma | 2 | 2000 | 436 | 0.050 |
Why?
|
| Knee Prosthesis | 1 | 2019 | 33 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2021 | 245 | 0.040 |
Why?
|
| Oxygen | 1 | 2004 | 726 | 0.040 |
Why?
|
| Cell Line | 2 | 2016 | 2476 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 3035 | 0.040 |
Why?
|
| Vagina | 1 | 2000 | 161 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2021 | 881 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 98 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2001 | 910 | 0.040 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2019 | 109 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 1999 | 177 | 0.040 |
Why?
|
| Pregnancy | 1 | 2004 | 2901 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2011 | 225 | 0.030 |
Why?
|
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 2015 | 17 | 0.030 |
Why?
|
| Stilbenes | 1 | 2015 | 25 | 0.030 |
Why?
|
| Aptamers, Nucleotide | 1 | 2015 | 23 | 0.030 |
Why?
|
| Mutagens | 1 | 2015 | 31 | 0.030 |
Why?
|
| Replication Protein A | 1 | 2015 | 16 | 0.030 |
Why?
|
| Virus Internalization | 1 | 2015 | 39 | 0.030 |
Why?
|
| Remission Induction | 2 | 2011 | 722 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 265 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2000 | 744 | 0.030 |
Why?
|
| Virus Replication | 1 | 2015 | 319 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 547 | 0.030 |
Why?
|
| SEER Program | 1 | 2013 | 190 | 0.030 |
Why?
|
| HIV Integrase | 1 | 2011 | 5 | 0.030 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2011 | 18 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 357 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 270 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 1286 | 0.020 |
Why?
|
| Time Factors | 1 | 1999 | 5215 | 0.020 |
Why?
|
| Risk Factors | 1 | 2001 | 5416 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 2011 | 439 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2011 | 301 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2007 | 76 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 1534 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 334 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 1204 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 4212 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1752 | 0.010 |
Why?
|
| Morbidity | 1 | 2000 | 148 | 0.010 |
Why?
|
| Fever | 1 | 2000 | 125 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2000 | 146 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 3977 | 0.010 |
Why?
|
| Hospitalization | 1 | 2000 | 851 | 0.010 |
Why?
|